Press Releases

Proceeds fully fund the company through 2028 and will be used to accelerate commercialization of Solidion's patented Extreme-Climate Battery Technology targeting the Lunar economy and space applications DALLAS, TX, June 07, 2026 (GLOBE NEWSWIRE) -- Solidion Technology Inc. ("Solidion" or the "Company") (NASDAQ:STI), an advanced battery technology solutions provider, today announced that it has entered into a securities purchase agreement with a new institutional investor for the purchase and sale of 2,333,000 shares of common stock (or common stock equivalents) in a private placement priced above market under Nasdaq rules. The offering is expected to result in gross proceeds of $35 milli

FF will hold its FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch at its Los Angeles headquarters on June 16, where the Company will give a full and in-depth introduction to FF's robotics education ecosystem strategy and also launch its EAI education product line and several major new EAI devices. On June 22, at Automate in Chicago, the largest robotics show in North America, FF will hold the FF EAI Robotics Multi-Form Lineup Debut & New Product Launch. FF will use this event to share more on its Three-in-One EAI ecosystem and EAI device lineup. Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or the "Company"), a Califo

SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or "Everest"), has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals ("CORXEL") to acquire the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest Medicines is a biopharmaceutical company focused on discovering, developing

Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company's financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company's discretion to support busines

News Summary: SK Telecom plans to build a gigawatt-scale AI Cloud in Korea using the NVIDIA DSX platform, with the first AI factory planned to come online in 2027.The AI Cloud will support sovereign, physical and agentic AI services for enterprises and industries across Korea, building on SK Telecom's network, data center and enterprise infrastructure expertise.NVIDIA DSX will serve as the AI factory architecture blueprint, combining NVIDIA accelerated computing, systems, software and partner technologies to improve time to production and token performance per megawatt.NVIDIA and SK Group are planning to expand their collaboration from AI infrastructure deployments to joint research on next

News Summary: NAVER, an AI Cloud, will build AI factories on the NVIDIA DSX platform at gigawatt scale, starting with AI infrastructure expansion at GAK Sejong.NVIDIA DSX gives NAVER a proven AI factory blueprint to serve Korea's industries and global AI cloud customers as demand for useful AI surges at lowest token cost.NAVER will use NVIDIA full-stack AI platforms, models and software to advance regional AI models including next-generation HyperCLOVA X models, its Seoul World Model development and agentic AI services. SEOUL, South Korea, June 07, 2026 (GLOBE NEWSWIRE) -- NVIDIA and NAVER today announced that NAVER will expand sovereign AI infrastructure, starting at 55 megawatts with p

News Summary: NVIDIA and SK hynix announce multiyear technology partnership for next-generation memory aligned to NVIDIA's AI infrastructure roadmap.The agreement supports supply for advanced memory, addressing the extended development cycles, advanced fabrication and capital investments to sustain the global buildout of AI factories.SK hynix will diversify into new markets NVIDIA is creating — across AI infrastructure, personal AI and physical AI — codeveloping memory for NVIDIA Vera Rubin AI supercomputers, Vera CPUs, RTX Spark-powered PCs and Jetson Thor robotic computing platforms.The two companies will apply AI to semiconductor chip design and manufacturing, using NVIDIA CUDA-X librari

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and e

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests. Plans to continue operations without interruption and it is business-as-usual for the Company in providing service for existing Medicare consumers and partners. CHICAGO, June 07, 2026 (GLOBE NEWSWIRE) -- GoHealth, Inc. ("GoHealth" or the "Company"), a health insurance marketplace and Medicare-focused digital health company, announced that GoHealth and certain of its subsidiaries have voluntarily filed chapter 11 petitions (the

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 ​ Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi

Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney Tunes Land media kit available HERE.LOS ANGELES, June 6, 2026 /PRNewswire/ -- Six Flags Magic Mountain is excited to announce that  Looney Tunes™ Land, a uniquely themed area with loveable characters, is now open. The refreshed family-friendly area has been reimagined where the timeless fun of Looney Tunes™ comes to life. Developed in partnership with Warner Bros. Discovery Global Experiences and designed for young adventurers and families alike, Looney Tunes Land brings together colorful environments, pl

What's happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperaturesWhy it matters: Acting now with a few simple steps can help reduce energy use during the heat waveCHARLOTTE, N.C., June 6, 2026 /PRNewswire/ -- High temperatures are forecast across the Carolinas this weekend and next week, and Duke Energy has tips to help you take control of your energy use while keeping you and your family cool. Tips to save energy and money Set your thermostat to the highest comfortable setting. Even a couple of degrees can help save energy and money. Keep in

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance  New data expands on findings shared at ATTD and reinforces Eversense 365's strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stag

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (NASDAQ:AIFA) ("AIFA" or the "Company") today provided a strategic update. Following the Company's previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group ("HyalRoute") and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an "AI infrastructure network powered by optical technologies" and an "AI application services matrix." The Company stated that, on June 5, AIFA Ch

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific